Good morning,
We have fourteen deals this week, taking in injectable drug manufacturing in Saarland, a SEK 3 billion campus acquisition in Sweden, and a giant office-to-lab conversion in London. Let's jump into it.
In today's free edition:
🇸🇪 Vectura acquires full ownership of GoCo Health Innovation City in SEK 3 billion deal
🇩🇪 Vetter Pharma to build €480 million injectable drugs production facility in Saarlouis
🇬🇧 Oaktree converts former Credit Suisse offices at Canary Wharf into 256,000 sq ft lab space
🇫🇷 Arizona and TPG Angelo Gordon reposition former Sanofi campus as Boost Campus near Paris
🔒 For paying members only:
🇬🇧 Kier appointed on £120 million eye clinic in Edinburgh
🇩🇪 BC Partners agrees sale of Infineon R&D campus in Warstein
🇪🇸 Vytrus Biotech to build €3.5 million production facility in Terrassa
🇫🇷 Pierre Expansion Santé acquires Biogroup laboratory unit in Paris
🇬🇧 IWG launches Humanly healthcare workspace in Kent
🇩🇪 Level Nine moves into new headquarters at Adlershof
🇬🇧 Bruntwood SciTech invests £3 million in Alderley Park
🇬🇧 Fleming Centre planned for Paddington
🇬🇧 Stanhope and Wilbe Labs open incubator at White City Place
🇩🇪 HI-TRON reaches topping-out at new Mainz oncology research building
Subscribe here to unlock.
Enjoy today's newsletter,
— Stephen Ryan (connect with me on LinkedIn)
Vectura acquires full ownership of GoCo Health Innovation City in SEK 3 billion deal
Investor AB's Patricia Industries subsidiary Vectura Fastigheter has agreed to acquire Next Step Group's stake in GoCo Health Innovation City in Mölndal, south of Gothenburg, giving Vectura full ownership of the life science cluster anchored by AstraZeneca's R&D hub.
The platform-level share transaction, announced on 17 February 2026, values the GoCo properties in the deal at around SEK 3 billion (€280 million), covering four life science-oriented buildings totalling about 52,000 sq m plus development rights within the mixed laboratory, R&D, office and innovation district.
Vetter Pharma to build €480 million injectable drugs production facility in Saarlouis
Vetter Pharma, a contract development and manufacturing organisation specialising in injectable drugs, is to build a new commercial production facility in Saarlouis, Saarland, with construction scheduled to begin in Q2 2026.
The company acquired the approximately 95-acre industrial site at the end of 2024.
The first construction phase is budgeted at approximately €480 million, forming part of a wider €1.5 billion investment plan spanning Europe and the United States.
Operations are expected to commence in 2031. The European Commission has approved up to €47 million in state aid for the project, which has the potential to create up to 2,000 jobs.
🔍 Need deeper insight into life sciences real estate?
In addition to this newsletter, we deliver bespoke research and strategic analysis for investors and developers — from acquisition support to market mapping and custom reporting. Get in touch to discuss your next project.
Oaktree converts former Credit Suisse offices at Canary Wharf into 256,000 sq ft lab space
Funds managed by Oaktree Capital Management, supported by LS Estates, are converting the former Credit Suisse offices at 17 Columbus Courtyard, Canary Wharf, into approximately 256,000 sq ft of high-specification laboratory and office space targeting the life sciences sector.
The office-to-lab retrofit will deliver CL2-capable space with a mix of fully fitted lab suites from around 1,500 sq ft alongside CAT A and shell-and-core accommodation.
Practical completion is targeted for Q3 2026 and space is being marketed as move-in ready from late 2026.
Arizona and TPG Angelo Gordon reposition former Sanofi campus as Boost Campus near Paris
Arizona Asset Management and TPG Angelo Gordon are repositioning the former Sanofi R&D campus at Chilly-Mazarin and Longjumeau, south of Paris, as Boost Campus, a health and technology innovation hub in the Paris–Paris-Saclay–Genopole "golden triangle" aligned with the France 2030 innovation strategy.
The scheme is being actively marketed with phased delivery milestones: 30,000 sq m of laboratories targeted for availability by Q2 2026, 60,000 sq m of production and industrial space by Q4 2027, an in vivo research platform operational by Q3 2026, and a 5–15 megawatt compute and sensitive-data storage centre planned for Q1 2028.
👇 As a free member, you're seeing only 4 of 14 deals this week. Subscribers see them all — why not take a 14-day trial?
